Optimizing treatment in paediatric rheumatology—lessons from oncology
Crossref DOI link: https://doi.org/10.1038/nrrheum.2015.50
Published Online: 2015-04-21
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Niehues, Tim
Text and Data Mining valid from 2015-04-21
Article History
First Online: 21 April 2015
Competing interests
: T.N. received speaker or consultant fees from Abbott, Baxter, Bristol Myers Squibb, CSL Behring, Essex-Pharma, Glaxo Smith-Kline, Novartis, Octapharma and Pfizer.